Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies

References

• Hanfei Xu MS, Cupples LA, Stokes A, Liu C-T. Association of obesity with mortality over 24 years of weight history findings from the framingham heart study. JAMA Netw Open. 2018;1(7):e184587. doi:10.1001/jamanetworkopen.2018.4587.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293(15):1861–7. doi:10.1001/jama.293.15.1861.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index cat egories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82. doi:10.1001/jama.2012.113905.
   PubMed Web of Science ®Google Scholar
• Prospective studies collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096. doi:10.1016/S0140-6736(09)60318-4.
   PubMed Web of Science ®Google Scholar
• Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602.
   PubMed Web of Science ®Google Scholar
• Klevorn LE, Teague RM. Adapting cancer immunotherapy model for the real world. Trends Immunol. 2016;37(6):354–363. doi:10.1016/j.it.2016.03.010.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass índex and risk of 22 specific cancers: a population-based cohort study of 5.24 million UD adults. Lancet. 2014;384(9945):755–765. doi:10.1016/S0140-6736(14)60892-8.
   PubMed Web of Science ®Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proponed mechanisms. Nat Rev Cancer. 2004;4(8):579–591. doi:10.1038/nrc1408.
   PubMed Web of Science ®Google Scholar
• Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC, Jee SH, Ansary-Moghaddam A, Jamrozik K, Ueshima H, et al. Body-mass índex and cancer mortality in the Asia-Pacific cohort studies collaboration: pooled analyses of 424,519 participants. Lancet Oncol. 2010;11(8):741–752. doi:10.1016/S1470-2045(10)70141-8.
   PubMed Web of Science ®Google Scholar
• Tao W, Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol. 2013;10(9):519–533. doi:10.1038/nrclinonc.2013.120.
   PubMed Web of Science ®Google Scholar
• Quante M, Dietrich A, Elkhal A, Tullius SG. Obesity-related immune responses and their impact on surgical outcomes. Int J Obes (Lond). 2015;39(6):877–883. doi:10.1038/ijo.2015.21.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625–1638. doi:10.1056/NEJMoa021423.
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol. 2013;8(9):1121–1127. doi:10.1097/JTO.0b013e31829cf942.
   PubMed Web of Science ®Google Scholar
• Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Zimmers TA. Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg. Res. 2011;170(1):e75–83. doi:10.1016/j.jss.2011.04.061.
   PubMed Web of Science ®Google Scholar
• Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, Vyfhuis M, Scilla KA, Feigenberg SJ, Edelman MJ, Feliciano JL, et al. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2017;104:52–57. doi:10.1016/j.lungcan.2016.11.017.
   PubMed Web of Science ®Google Scholar
• Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee J-L, Rini BI, Srinivas S, Bjarnason GA et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 2016 Oct 20;34(30):3655–3663. doi:10.1200/JCO.2016.66.7311.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu Y, Shao H, Zheng C. Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications. J Thorac Oncol. 2017 Oct;12(10):1478–1488. doi:10.1016/j.jtho.2017.07.022.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne P-L, Bedenne L, Bennouna J, Phelip J-M, et al. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Eur J Cancer. 2018 Jul;98:1–9. doi:10.1016/j.ejca.2018.03.031.
   PubMed Web of Science ®Google Scholar
• Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 Jan;25(1):141–151. doi:10.1038/s41591-018-0221-5.
   PubMed Web of Science ®Google Scholar
• Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, Richtig M, Grübler MR, Gappmayer A, Haidn T, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS One. 2018;13(10):e0204729. doi:10.1371/journal.pone.0204729.
   PubMed Web of Science ®Google Scholar
• Mcquade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, et al. Association of body-mass índex and outcomes in patients metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322. doi:10.1016/S1470-2045(18)30078-0.
   PubMed Web of Science ®Google Scholar
• Murphy WJ, Longo DL. The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA. 2019 Mar 18;321(13):1247. doi:10.1001/jama.2019.0463.
   PubMed Web of Science ®Google Scholar
• Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019 Jan 22;109:21–27. doi:10.1016/j.ejca.2018.10.014.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283–1294. doi:10.1016/S1470-2045(16)30167-X.
   PubMed Web of Science ®Google Scholar
• Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA et al. Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019 Mar 20;37(9):693–702. doi:10.1200/JCO.18.01896.
   PubMed Web of Science ®Google Scholar
• WHO. Health topics. Obesity. [accessed 2020 Apr 12]. https://www.who.int/topics/obesity/en
   Google Scholar
• NIH. Classification of overweight and obesity by BMI, waist circumference, and associated disease risks. [accessed 2020 Apr 12]. https://www.nhlbi.nih.gov/
   Google Scholar
• Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW et al. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018 Dec 1;24(23):5841–5849. doi:10.1158/1078-0432.CCR-18-0415.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143e52. doi:10.1016/S1470-2045(17)30074-8.
   Web of Science ®Google Scholar